Aurora Cannabis Converts 99% of $230 Million Convertible Debenture Into 69 Million Shares

Aurora Cannabis (TSX: ACB) (NYSE: ACB) announced this morning that their early conversion option on its $230 million worth of convertible debentures due in March 2020 was a resounding success. Approximately $227.0 million worth of debt has now been converted into equity at the early conversion price, which is a notable improvement from the previous update of $216.0 million.

While excellent for Aurora’s balance sheet, the early conversion option was trivial to shareholders. The Deep Dive has reported on the matter extensively, including the resulting slide in the share price following the announcement. The early conversion price was based on a five day volume weight average price, from the period of November 18, 2019 to November 22, with the resulting convert price being C$3.2837.

As a result of the early conversion, a total 69,135,117 common shares were issued.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

Any current and future unpaid interest on the debt, up to but not including March 9, 2020, was paid out by Aurora in the form of cash. A total cash figure was not provided by the issuer.

A total of $2.3 million is expected to be remaining of the original $230 million convertible debenture. That debt will come due on March 9, 2020.

Aurora Cannabis last traded at $3.58 on the TSX.


Information for this briefing was found via Sedar and Aurora Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A $2.2B Gold Project Is Outgrowing Its Plan | Michael Henrichsen – Gold X2 Mining

Pay for the Copper, Get the Gold Free | Rob McEwen – McEwen Inc

This Gold Discovery Was Already Huge. Now It’s Becoming a Monster. | Goliath Resources

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Aurora clear winner in Big 5 quarterly results

Three of Canada’s Big 5 cannabis producers have now reported their quarterly earnings this year,...

Tuesday, February 19, 2019, 02:00:30 PM

Canaccord Lowers Aurora Cannabis Price Target To $5 Following Q2 Earnings

On February 10th, Aurora Cannabis (TSX: ACB) reported its fiscal second quarter 2022 results. The...

Sunday, February 13, 2022, 05:16:00 PM

Aurora Cannabis Begins Outsourcing Manufacturing With Initial Valens Company Agreement

Aurora Cannabis (TSX: ACB) appears to be in the process of changing its business model....

Thursday, October 28, 2021, 07:54:57 AM

Aurora Cannabis Suggests Curaleaf’s Bid Is Capped Too Low

Aurora Cannabis (TSX: ACB) has responded to Curaleaf’s (TSX: CURA) announcement that it intends to...

Wednesday, August 12, 2026, 09:53:16 AM

Aurora Cannabis Posts Record EBITDA But Free Cash Flow Remains In The Red

Aurora Cannabis Inc. (TSX: ACB) reported strong results in its fiscal Q2 2025 earnings, posting...

Wednesday, November 6, 2024, 09:15:46 AM